

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of June 2019**

Commission File Number: **001-35165**

**BRAINSWAY LTD.**

(Translation of registrant's name into English)

**19 Hartum Street  
Bynet Building, 3rd Floor  
Har HaHotzvim  
Jerusalem, 9777518, Israel**  
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

The following document, which is attached as an exhibit hereto, is incorporated by reference herein:

Exhibit	Title
<a href="#">99.1</a>	<a href="#">New Data Published in American Journal of Psychiatry Further Substantiates BrainsWay's Deep TMS System for the Treatment of Patients with Obsessive Compulsive Disorder</a>

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**BRAINSWAY LTD.**  
(Registrant)

Date: June 27, 2019

/s/ Hadar Levy  
Hadar Levy  
Chief Financial Officer

## New Data Published in American Journal of Psychiatry Further Substantiates BrainsWay's Deep TMS System for the Treatment of Patients with Obsessive Compulsive Disorder

- First non-invasive device for OCD achieves 45% response rate among patients after one month follow up, and significantly reduced symptoms scores compared with placebo -

HACKENSACK, N.J., June 27, 2019 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ: BWAY, TASE: BWAY), a global leader in the advanced, non-invasive treatment of brain disorders, today announced new data from an article published in the last issue of the *American Journal of Psychiatry* demonstrating that its Deep TMS (dTMS) System showed a significant clinical benefit compared with placebo to treat Obsessive Compulsive Disorder (OCD) in a ~100-patient clinical trial (NCT02229903). OCD is a chronic and disabling disorder that affects ~1% of US adults. BrainsWay's Deep TMS OCD treatment received De Novo clearance from the U.S. Food and Drug Administration (FDA) in August 2018 and is the only TMS platform that is FDA-cleared to treat OCD.

BrainsWay's Deep TMS system provides OCD patients with a non-invasive, personalized treatment option that augments existing therapeutic approaches, including pharmacological or psychological therapy.

"We need new treatment options for OCD because current psychological therapies and medications often yield unsatisfactory results," said David Feifel MD, PhD, Professor Emeritus of Psychiatry at the University of California, San Diego, Director of Kadima Neuropsychiatry Institute and an investigator in the study. "The results of this clinical study demonstrate that Deep TMS performed daily for six weeks can significantly improve OCD symptoms and is safe and well-tolerated. It is particularly impressive that the improvement in symptoms was comparable to the average improvement we often see with a standard course of medications alone for 12 weeks, but was produced in half the time, and with fewer side effects. Importantly, these improvements lasted for at least a month after the treatment was stopped. Patients in the study all had moderate to severe OCD symptoms despite taking medications for OCD. These results suggest that this innovative, non-invasive and personalized adjunct approach can provide a measurable benefit to those OCD patients who continue to struggle with debilitating symptoms despite receiving the best available drug treatments."

Click to Tweet: "These results suggest that this innovative, non-invasive & personalized approach can provide a measurable benefit to OCD patients who struggle w/ debilitating symptoms despite receiving the best available drug treatments." Dr. David Feifel, Kadima Neuropsychiatry Institute

### About The Study

The data published in the *American Journal of Psychiatry* are from a double-blind, placebo-controlled, multicenter, FDA-regulated clinical trial that compared the effects of high-frequency (20Hz) dTMS to that of sham treatment (placebo) administered daily for six weeks on patients with OCD symptoms as assessed using the Yale-Brown Obsessive-Compulsive-Scale (Y-BOCS).

The primary efficacy endpoint was the change in Y-BOCS scale from baseline to post-treatment. Secondary efficacy endpoints were the proportion of patients who achieved full response and partial response, defined as 30% or 20% reduction, respectively, in Y-BOCS scores from baseline to post-treatment, changes at follow-up four weeks post-treatment, and other scales listed below.

The trial was conducted at 11 clinical centers, among OCD patients who had inadequate responses to pharmacological therapy with serotonin reuptake inhibitors (SRIs) or who failed or had inadequate responses to cognitive behavioral therapy (CBT). Deep TMS treatment was given as an adjunct therapy in addition to the patients' current method of treatment whether pharmacological or CBT. Prior to each treatment session, patients underwent a 3-5 minute individualized symptom provocation in order to activate their OCD circuitry. A total of 94 patients who received at least one active/placebo treatment and met the study eligibility criteria were included in the FDA-approved main analysis set. Key findings from the study include:

- 1 There was a significantly greater reduction in Y-BOCS scores in patients treated with dTMS compared with placebo (-6.0 points vs. -3.3 points,  $p=0.01$ ) for an effect size of 0.69 following six weeks of daily treatment. This benefit was maintained at one-month follow-up, with Y-BOCS reductions of -6.5 and -4.1 points for the dTMS and placebo groups, respectively ( $p=0.03$ ) for an effect size of 0.62.
- 1 The full response rate (Y-BOCS reduction  $\geq 30\%$ ) at the end of treatment was significantly higher in the dTMS group (38.1%) compared with the placebo group (11.1%),  $p=0.003$ . This improvement was also maintained at one-month follow-up (45.2% vs. 17.8%, respectively,  $p=0.0057$ ).
- 1 The partial response rate (Y-BOCS reduction  $\geq 20\%$ ) at the end of treatment was significantly higher in the dTMS group (54.8%) compared with the placebo group (26.7%),  $p=0.0076$ . This improvement was also maintained at one-month follow-up (59.5% vs. 42.2%, respectively), although this later difference was not statistically significant ( $p=0.1059$ ).
- 1 The clinicians' global impression of improvement (CGI-I), a measure of global improvement functioning, was statistically different between the active dTMS group, with 49% being assessed as moderate to very much globally improved compared to 21% of the sham group ( $p=0.011$ ).
- 1 The change from baseline in the clinicians' global impression of severity (CGI-S), a measure of global severity of functioning, was found to be statistically significant at the post-treatment assessment, with 61% of dTMS subjects demonstrating improvement, compared to 32.6% of sham ( $p=0.022$ ).
- 1 There was no statistically significant difference in the numbers and types of adverse events in the dTMS and placebo groups. Typical to TMS studies, headache was the most common adverse event in both the dTMS and placebo groups (37.5% and 35.3%, respectively) and was not significantly different between the groups.
- 1 There were no significant adverse events reported due to the dTMS treatment.
- 1 There was no significant difference in the dropout rate between the dTMS and placebo groups (10% each).

"The mechanism of action of this treatment is quite different from that of current medications," said Prof. Abraham Zangen, a scientific founder and a neurobiological consultant for BrainsWay. "The brain region targeted in this pivotal trial with the Deep TMS H7 coil is the anterior cingulate cortex, a region known for decades to be centrally implicated in the pathophysiology of OCD. Modulation of the relevant neural networks by Deep TMS following an individualized psychological provocation procedure, which is part of the treatment protocol, allows a gradual and stable neuroplastic change - resulting in an effective treatment for millions of OCD patients who do not sufficiently respond to medications or psychotherapies."

The authors of the paper also refer to a recent meta-analysis of 17 studies demonstrating that SRIs were superior to placebo for OCD with an average 3.2 points weighted mean difference on the YBOCS after 10-13 weeks of treatment. This dTMS study recruited patients who were moderately to severely symptomatic (mean YBOC=28) despite being treated with medications, and in many cases, also psychotherapy. They improved within six weeks of treatment using Deep TMS as an adjunct therapy, and their improvement continued even after they completed their six weeks of treatment.

"The positive results seen in this population of patients, who have not sufficiently benefited from SRIs or CBT, further validate Deep TMS as a uniquely effective treatment option," said Yaacov Michlin, CEO of BrainsWay. "The study authors suggest that dTMS should be considered at the early stages of treatment if patients fail to have an adequate

response to appropriate psychological or pharmacological therapy. We believe this data and the authors' conclusions add to the growing body of evidence supporting the use of dTMS as a standard adjunct component of OCD therapy."

#### **About OCD**

More than 2 million adults in the United States suffer from obsessive-compulsive disorder (OCD). It is a severe, chronic psychiatric disease characterized by a pattern of obsessive thoughts and compulsive repetitive behaviors, which has a significantly destructive effect on patients' day-to-day activities. Current treatment options include SSRI antidepressant medications, which must be given at very high doses for OCD patients, cognitive-behavioral therapy (CBT), or a combination of these treatment options. OCD is very difficult to treat since many patients do not respond to medication or CBT, and many have difficulty tolerating the side effects of pharmacological treatment.

#### **About BrainsWay**

BrainsWay is engaged in the research, development and sales and marketing of a medical system for non-invasive treatment of common brain disorders. The medical system developed and manufactured by the company is based on a unique breakthrough technology called Deep TMS, which can reach significant depth and breadth of the brain and produce broad stimulation and functional modulation of targeted brain areas. In the U.S., the Company's device has been FDA cleared for the treatment of major depressive disorder (MDD), and is now FDA cleared (De Novo) for the treatment of Obsessive Compulsive Disorder (OCD). The Company's systems have also received CE clearance and are sold worldwide for the treatment of various brain disorders. Deep TMS is eligible for reimbursement in the US for MDD and the company is currently working on obtaining reimbursement for OCD.

#### **Forward-Looking Statement**

This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. These forward-looking statements and their implications are based on the current expectations of the management of the Company only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our device studies; our products may not be approved by regulatory agencies; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in BrainsWay Ltd.'s periodic filings with the U.S. Securities and Exchange Commission.

#### **Media Contact:**

Erich Sandoval  
Lazar Partners  
Phone: +1 917-497-2867  
esandoval@lazarpartners.com